AR014464A1 - Anticuerpo monoclonal y sus fragmentos que se dirigen contra las celulas que portan integrinas alfavbeta la linea de celulas de hibridoma que producedicho anticuerpo, las composiciones farmaceuticas que lo contienen, un procedimiento para su preparacion, y el empleo del mismo en procesos tumorales - Google Patents
Anticuerpo monoclonal y sus fragmentos que se dirigen contra las celulas que portan integrinas alfavbeta la linea de celulas de hibridoma que producedicho anticuerpo, las composiciones farmaceuticas que lo contienen, un procedimiento para su preparacion, y el empleo del mismo en procesos tumoralesInfo
- Publication number
- AR014464A1 AR014464A1 ARP990100258A ARP990100258A AR014464A1 AR 014464 A1 AR014464 A1 AR 014464A1 AR P990100258 A ARP990100258 A AR P990100258A AR P990100258 A ARP990100258 A AR P990100258A AR 014464 A1 AR014464 A1 AR 014464A1
- Authority
- AR
- Argentina
- Prior art keywords
- monoclonal antibody
- processing
- integrin
- cells
- fragments
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 4
- 108010044426 integrins Proteins 0.000 abstract 4
- 102000006495 integrins Human genes 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000000758 substrate Substances 0.000 abstract 2
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 102000016359 Fibronectins Human genes 0.000 abstract 1
- 108010067306 Fibronectins Proteins 0.000 abstract 1
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 108010045077 integrin alphaVbeta5 Proteins 0.000 abstract 1
- 108010004788 integrin alphavbeta6 Proteins 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Un anticuerpo monoclonal y sus fragmentos, que tienen las propiedades siguientes: reaccionan solamente con la cadena alfaV de las integrinas alfaaVhumanas e inhiben selectivamente la union al sustrato de integrina fibronectina de la célula portadora de alfaVBeta6. La línea de células de hibridoma quetiene la denominacion de 271.14D9.F8 y está depositada con el numero de acceso DSM ACC2331, y que es capaz de producir un anticuerpo monoclonal como eldescripto más arriba. Una composicion farmacéutica que comprende un anticuerpo monoclonal como el descripto y un vehículo aceptable desde el punto de vistafarmacéutico. Un procedimiento para producir un anticuerpo monoclonal como el descripto más arriba, por inmunizacion de un raton conla línea de células M21de tumor humano. El empleo del anticuerpo monoclonal para obtener un remedio contra tumores, preferentemente una célula de carcinoma de colon opulmon, opara la ubicacion y determinacion diagnosticas del crecimiento del tumor. El estado de la técnica describe anticuerpos que apuntan a todas las integrinasalfaVs complejos alfaVBeta3 o alfaVbeta5, pero no describe reactivo alguno que inhiba selectivamente la serie alfaVbeta6. Es por eso que el presente inventoprovee unanticuerpo monoclonal que reacciona solamente con la cadena alfaV de las integrinas alfaV humanas y bloquea selectivamente la union al sustrato deintegrina de la célula portadora de la integrina alfaVbeta3 y alfaVbeta6, y que se denomina 14D9.F8.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98101108 | 1998-01-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR014464A1 true AR014464A1 (es) | 2001-02-28 |
Family
ID=8231295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990100258A AR014464A1 (es) | 1998-01-23 | 1999-01-22 | Anticuerpo monoclonal y sus fragmentos que se dirigen contra las celulas que portan integrinas alfavbeta la linea de celulas de hibridoma que producedicho anticuerpo, las composiciones farmaceuticas que lo contienen, un procedimiento para su preparacion, y el empleo del mismo en procesos tumorales |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1049718B1 (es) |
| JP (1) | JP2002501086A (es) |
| KR (1) | KR20010034327A (es) |
| CN (1) | CN1168741C (es) |
| AR (1) | AR014464A1 (es) |
| AT (1) | ATE322508T1 (es) |
| AU (1) | AU2716399A (es) |
| BR (1) | BR9907218A (es) |
| CA (1) | CA2319160A1 (es) |
| DE (1) | DE69930723T2 (es) |
| HU (1) | HUP0101151A3 (es) |
| ID (1) | ID27810A (es) |
| NO (1) | NO20003767D0 (es) |
| PL (1) | PL341569A1 (es) |
| SK (1) | SK10772000A3 (es) |
| WO (1) | WO1999037683A1 (es) |
| ZA (1) | ZA99453B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| WO2002085405A2 (en) | 2001-04-24 | 2002-10-31 | Merck Patent Gmbh | COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a) |
| CA2453403C (en) | 2001-07-09 | 2013-10-08 | Elan Pharmaceuticals, Inc. | Methods of inhibiting amyloid toxicity |
| US7829087B2 (en) | 2001-07-09 | 2010-11-09 | Elan Pharmaceuticals, Inc. | Methods of treating cognitive impairment |
| BRPI0308585B8 (pt) * | 2002-03-13 | 2021-05-25 | Biogen Idec Inc | anticorpo isolado ou fragmento de ligação a antígeno do mesmo que se liga à alfavbeta6, composição, método de detecção in vitro de alfavbeta6 e construção de dna |
| CN102875681A (zh) * | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| WO2007084670A2 (en) | 2006-01-18 | 2007-07-26 | Merck Patent Gmbh | Specific therapy using integrin ligands for treating cancer |
| US20090220504A1 (en) | 2006-03-21 | 2009-09-03 | Anan Chuntharapai | Combinatorial therapy |
| WO2008008315A2 (en) | 2006-07-10 | 2008-01-17 | Biogen Idec Ma Inc. | Compositions and methods for inhibiting growth of smad4-deficient cancers |
| RU2009107277A (ru) | 2006-08-03 | 2010-09-10 | Астразенека Аб (Se) | АНТИТЕЛА, НАЦЕЛЕННЫЕ НА αVβ6, И ИХ ПРИМЕНЕНИЕ |
| PL2101805T3 (pl) | 2007-01-18 | 2013-04-30 | Merck Patent Gmbh | Ligandy integryn do stosowania w leczeniu nowotworów |
| CL2008002856A1 (es) | 2007-09-26 | 2009-01-16 | Genentech Inc | Anticuerpo novedoso (anticuerpo anti-integrina a5b1; mol}ecula de ácido nucleico que lo codifica; vector y célula huesped; método de producción; composición farmacéutica que lo comprende; su uso para inhibir la angiogénesis y/o permeabilidad vascular y cáncer entre otras patologías; y método de detección de la integrina a5b1). |
| WO2009061448A2 (en) | 2007-11-08 | 2009-05-14 | The General Hospital Corporation | Methods and compositions for the treatment of proteinuric diseases |
| AU2010229479B2 (en) | 2009-03-25 | 2013-03-28 | Genentech, Inc. | Novel anti-alpha5beta1 antibodies and uses thereof |
| SG176103A1 (en) | 2009-05-25 | 2011-12-29 | Merck Patent Gmbh | Continuous administration of cilengitide in cancer treatments |
| MX342270B (es) * | 2010-02-18 | 2016-09-21 | The Regents Of The Univ Of California * | ANTICUERPO NEUTRALIZANTE DE LA INTEGRINA AVß8. |
| WO2014143739A2 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
| WO2014144466A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69531187T2 (de) * | 1994-12-20 | 2004-04-22 | Merck Patent Gmbh | Monoklonaler Antikörper gegen das Alpha-V-Integrin |
-
1999
- 1999-01-11 ID IDW20001566A patent/ID27810A/id unknown
- 1999-01-11 DE DE69930723T patent/DE69930723T2/de not_active Expired - Lifetime
- 1999-01-11 SK SK1077-2000A patent/SK10772000A3/sk unknown
- 1999-01-11 CA CA002319160A patent/CA2319160A1/en not_active Abandoned
- 1999-01-11 JP JP2000528603A patent/JP2002501086A/ja active Pending
- 1999-01-11 PL PL99341569A patent/PL341569A1/xx unknown
- 1999-01-11 HU HU0101151A patent/HUP0101151A3/hu unknown
- 1999-01-11 EP EP99907361A patent/EP1049718B1/en not_active Expired - Lifetime
- 1999-01-11 KR KR1020007008052A patent/KR20010034327A/ko not_active Application Discontinuation
- 1999-01-11 CN CNB998022829A patent/CN1168741C/zh not_active Expired - Fee Related
- 1999-01-11 BR BR9907218-1A patent/BR9907218A/pt not_active IP Right Cessation
- 1999-01-11 WO PCT/EP1999/000101 patent/WO1999037683A1/en active Search and Examination
- 1999-01-11 AT AT99907361T patent/ATE322508T1/de not_active IP Right Cessation
- 1999-01-11 AU AU27163/99A patent/AU2716399A/en not_active Abandoned
- 1999-01-21 ZA ZA9900453A patent/ZA99453B/xx unknown
- 1999-01-22 AR ARP990100258A patent/AR014464A1/es not_active Application Discontinuation
-
2000
- 2000-07-21 NO NO20003767A patent/NO20003767D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69930723T2 (de) | 2006-11-16 |
| JP2002501086A (ja) | 2002-01-15 |
| SK10772000A3 (sk) | 2001-01-18 |
| AU2716399A (en) | 1999-08-09 |
| ATE322508T1 (de) | 2006-04-15 |
| KR20010034327A (ko) | 2001-04-25 |
| BR9907218A (pt) | 2000-10-24 |
| PL341569A1 (en) | 2001-04-23 |
| EP1049718A1 (en) | 2000-11-08 |
| NO20003767L (no) | 2000-07-21 |
| CA2319160A1 (en) | 1999-07-29 |
| WO1999037683A1 (en) | 1999-07-29 |
| HUP0101151A2 (hu) | 2001-08-28 |
| CN1168741C (zh) | 2004-09-29 |
| NO20003767D0 (no) | 2000-07-21 |
| EP1049718B1 (en) | 2006-04-05 |
| ZA99453B (en) | 1999-07-21 |
| DE69930723D1 (de) | 2006-05-18 |
| ID27810A (id) | 2001-04-26 |
| CN1288469A (zh) | 2001-03-21 |
| HUP0101151A3 (en) | 2004-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR014464A1 (es) | Anticuerpo monoclonal y sus fragmentos que se dirigen contra las celulas que portan integrinas alfavbeta la linea de celulas de hibridoma que producedicho anticuerpo, las composiciones farmaceuticas que lo contienen, un procedimiento para su preparacion, y el empleo del mismo en procesos tumorales | |
| Chang et al. | Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium | |
| CA2798778C (en) | Anti-human trop-2 antibody having anti-tumor activity in vivo | |
| McIntosh et al. | NCL-CD10–270: a new monoclonal antibody recognizing CD10 in paraffin-embedded tissue | |
| KR101936697B1 (ko) | 항-her2 항체 및 이의 접합체 | |
| ES2641525T3 (es) | Anticuerpos que se unen a CA 125/0722P asociado a células y métodos de uso de los mismos | |
| ES2666131T3 (es) | Anticuerpos de mesotelina y métodos para provocar una potente actividad antitumoral | |
| US5744585A (en) | Human monoclonal antibody against lung carcinoma | |
| US10548987B2 (en) | Antibody-drug conjugates for targeting CD56-positive tumors | |
| JP3387929B2 (ja) | ＣＤ４４ｖ６に対するモノクローナル抗体 | |
| RU2009148600A (ru) | Химерные и гуманизированные антитела к cd44, которые опосредствуют цитотоксичность в отношении раковых клеток | |
| CA2395053A1 (en) | Novel serpentine transmembrane antigens expressed in human cancers and uses thereof | |
| Keler et al. | Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fcγ receptor type I-expressing effector cells | |
| KR920702692A (ko) | 인체 암종과 반응성인 신규 항체 | |
| CN104059150A (zh) | 结合epha2的抗体及其使用方法 | |
| JP2003500015A5 (es) | ||
| Oshikiri et al. | RCAS1 as a tumour progression marker: an independent negative prognostic factor in gallbladder cancer | |
| WO2003055515A1 (en) | Individualized anti-cancer antibodies | |
| Kieffer et al. | Expression of platelet glycoprotein Ib alpha in HEL cells. | |
| Harris et al. | Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59 | |
| Neville et al. | Monoclonal antibodies and human tumor pathology | |
| JP2020536557A (ja) | プロスタグランジンｆ２受容体阻害剤に対するモノクローナル抗体及びコンジュゲート、並びにそれらの使用 | |
| BR0213968A (pt) | Anticorpos humanos que apresentam ligação à proteìna superficial celular "mn" e atividade neutralizadora de aderência celular | |
| CN108431043A (zh) | 新颖的抗mmp16抗体及使用方法交叉引用的申请 | |
| Ricci et al. | HER/erbB receptors as therapeutic targets of immunotoxins in human rhabdomyosarcoma cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |